A photo of Sonata Jodele.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Professor, UC Department of Pediatrics



My Biography & Research


Dr. Jodele is an international expert in all aspects of transplant- associated thrombotic microangiopathy (TMA), clinical and research. She made major contributions to the field by linking TMA pathophysiology to the complement pathway, demonstrating the relationship of the disease to specific clinical and genetic factors, and then establishing a new paradigm for therapy with inhibition of the complement pathway. She is a leader in ongoing research efforts to develop new and better therapies for TMA. Due to her extensive experience in the care of complex transplant patients Dr. Jodele leads multi-disciplinary international collaborative groups and research projects around the world with clinicians and scientists from Germany, Switzerland, Italy and Japan.

Dr. Jodele serves as a clinical consultant for the physicians throughout the world regarding care of complex patients with this disorder. Dr. Jodele led the first prospective TMA biomarker and genetic predisposition studies. These studies resulted in practical applications to clinical care and also comprehensive diagnostic laboratory panels that are now offered for national and international patients. She also proposed new diagnostic algorithms and risk stratification criteria for TMA to guide timely initiation of therapy.

Dr. Jodele piloted novel complement blocking therapeutic agents for HSCT recipients with severe TMA and described unique drug pharmacokinetics in this patient population. This work led to the opening of first prospective early intervention clinical study at four major pediatric centers in USA using eculizumab for stem cell transplant recipients with high risk TMA. Dr. Jodele’s research is supported by the NIH, as well as institutional and industry sponsored grants.

Clinical Interests

Bone marrow transplantation and cellular therapies

Research Interests

Thrombotic microangiopathies; organ toxicity prevention in transplant patients

Academic Affiliation

Professor, UC Department of Pediatrics


Bone Marrow Transplantation BMT, Bone Marrow Transplantation, Cancer and Blood Diseases

My Education

MD: Vilnius University School of Medicine, Vilnius, Lithuania, 1988-1994.

Residency: Pediatrics, SUNY Health Science Center at Brooklyn, Brooklyn, NY, 1998-2001.

Fellowship: Pediatric Hematology/Oncology, Children's Hospital Los Angeles and Saban Research Institute, Keck School of Medicine University of Southern California, Los Angeles, CA, 2001-2004.

Certifications: Pediatrics, 2001; Pediatric Hematology / Oncology, 2004.

Licenses: California, 2001-present; Ohio, 2004-present.

My Publications

Jodele S. Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies (TA-TMA). Semin Hematol. 2018 Jul;55(3):159-166. Invited Review.

Jodele S, Dandoy CE, Myers KC, Wallace G, Lane A, Teusink-Cross A, Weiss B and DaviesSM. High dose Carboplatin/Etoposide/Melphalan Increases Risk of Thrombotic Microangiopathy and Organ Injury after Autologous Stem Cell Transplantation in Patients with Neuroblastoma. Bone Marrow Transplant. 2018 Apr 19.

Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Bone Marrow Transplant. 2015 Oct 19.

Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, Lane A, Meller J, Medvedovic M, Chen J, Davies SM. The genetic fingerprint of susceptibility for transplant associated thrombotic microangiopathy. Blood. 2015 Nov 24.

Dandoy CE, Davies SM, Hirsch R, Chima RS, Paff Z, Cash M, Ryan TD, Lane A, El-Bietar J, Myers KC, Jodele S. Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy. Biol Blood Marrow Transplant. 2015 Jan;21(1):113-8.

Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, El-Bietar J, Wallace G, Chima RS, Paff Z, Laskin BL. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a prospective study in children and young adults. Blood. 2014 May 29.

Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Biol Blood Marrow Transplant. 2013 Dec 25.

Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Jun 27.

Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplant associated-thrombotic microangiopathy. Blood. 2011 May 19.

Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.